{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.26","upperLimit":"4.53","value":"3.84"},{"groupId":"OG001","lowerLimit":"5.43","upperLimit":"7.50","value":"6.38"}]}],"title":"Baseline flare: hsCRP [N=107, 110]"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.95","upperLimit":"8.04","value":"6.31"},{"groupId":"OG001","lowerLimit":"12.58","upperLimit":"19.98","value":"15.85"}]}],"title":"Baseline flare: SAA [N=95, 104]"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.44","upperLimit":"5.60","value":"3.69"},{"groupId":"OG001","lowerLimit":"3.23","upperLimit":"5.60","value":"4.32"}]}],"title":"Last post-baseline flare: hsCRP [N= 22, 42]"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.56","upperLimit":"12.78","value":"6.74"},{"groupId":"OG001","lowerLimit":"7.17","upperLimit":"17.02","value":"11.04"}]}],"title":"Last post-baseline flare: SAA, [N= 19, 39]"}],"denoms":[{"counts":[{"groupId":"OG000","value":"112"},{"groupId":"OG001","value":"114"}],"units":"Participants"}],"description":"High sensitivity C-reactive protein (hsCRP) and serum amyloid A (SAA) were determined in blood serum in order to identify the presence of inflammation, to determine its severity, and to monitor the response to treatment. Analyses were measured by a central laboratory. The analysis included treatment group, log-transformed protein level at baseline, and body mass index (BMI) at baseline as covariates.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 1 subcutaneous (sc) injection of canakinumab 150 mg and 1 intramuscular (im) injection of placebo to triamcinolone acetonide on Day 1. Participants could receive a re-dose of study drug on demand upon the occurrence of new flares, but re-dosing could not occur until 14 days had elapsed after the previous dose. In the first extension study participants completing the 12 week core study could continue to be treated on demand with the same treatment for another 12 weeks for any new gout flare.","id":"OG000","title":"Canakinumab 150 mg"},{"description":"Participants received 1 intramuscular injection of triamcinolone acetonide 40 mg and 1 sc injection of placebo to canakinumab on Day 1. Participants could receive a re-dose of study drug on demand upon the occurrence of new flares, but re-dosing could not occur until 14 days had elapsed after the previous dose.\n\nIn the first extension study participants completing the 12 week core study could continue to be treated on demand with the same treatment for another 12 weeks for any new gout flare.","id":"OG001","title":"Triamcinolone Acetonide 40 mg"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"For the Baseline flare the population analyzed consisted of the Full Analysis Set (FAS). For the last post-baseline flare the population analyzed consisted of patients re-treated for at least one new flare. \"N\" indicates the number of participants with available data in each analysis.","reportingStatus":"POSTED","timeFrame":"72 hours after the first dose for the baseline flare and 72 hours post-dose for the last post-baseline flare that occurred up until the end of the first extension study (24 weeks).","title":"High-sensitivity C-reactive Protein (hsCRP) and Serum Amyloid A Protein (SAA) Levels","type":"SECONDARY","unitOfMeasure":"mg/L"}